There wont be anythign in the quarterly that we dont already...

There wont be anythign in the quarterly that we dont already know.

Alkili isnt 2 years away , it is now, they are contributing to the FDA, with cash - says to me they want it to get cleared, why else support it getting clearance... trials are already underway for FDA and data is being collected... On FDA approval there is also a $2m payment to TD1.

The device is probably a class one device so approval process is easier than class 2 and class 3 devices. Meaning cheaper and faster..

And there are directors buying, and more over the last 2 days shows there is no cap raise coming. But unfortunately it also shows they aren't close to a material announcement of a new deal in another jurisdiction.
The share price pull back is mostly on fear of cap raise (and with the market in the last week or so).

Any way I cut the Alkili deal ii completely underpins a multiple of current share price (as long as they get FDA approval - thats the only road block to sales in the US), but the market doesn't like waiting circa 12m for sales.

The short story here is, can Alkili drive meaningful sales and therefore milestone and royalty payments... Noting that the cost to TD1 of these sales is basically nil which is actually why this is a great deal, WOuldnt surprise me if the margin is circa 85-90% on the royalties as there is not much cost other than keeping the app up to date and patching bugs etc.